The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Glucocorticoid Use for Rheumatoid Arthritis Still Sparks Debate

Glucocorticoid Use for Rheumatoid Arthritis Still Sparks Debate

June 15, 2015 • By Anand N. Malaviya, MD, FRCP, Master-ACR

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Glucocorticoids: The Debate Continues

Déjà vu … In past decades, rheumatologists have seen, heard, practiced and taught much of what has been argued in the “ongoing debate” on the use of glucocorticoids (GCs) in the management of rheumatoid arthritis (RA).1 It is heartening to note that eminent professors have stuck to their premise all these years, as have I for decades (see “To Give or Not to Give? Debate continues over place of glucocorticoids in RA management,” The Rheumatologist, March 2015).

You Might Also Like
  • Glucocorticoid Use in Rheumatoid Arthritis Management Focus of Ongoing Debate
  • 2013 ACR/ARHP Annual Meeting: The Rheumatoid Arthritis Treatment Debate
  • Remission of Rheumatoid Arthritis Tied to Lower Risk of Metabolic Syndrome
Explore This Issue
June 2015

Having worked in India for most of my professional career, I may add to the confusion. Asian Indians as a race do not tolerate GCs well. The reason could possibly be that Asian Indians are highly prone to metabolic syndrome.2,3 Given even in small daily doses, GCs have adverse effects, mostly related to the metabolic syndrome.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Poverty is the second related issue. This puts biologicals out of reach for most. Therefore, in India we mostly use DMARD combos with bridging therapy, by way of depot-GC injections or orally for a short term. However, this creates problems. Because GCs are the cheapest and the most powerful pain reliever, the patient quickly perceives this as the real drug. With inherent difficulties in travel to reach a rheumatologist (e.g., poor facilities for differently abled persons in India) and the involved expense, they fall back on the magic pill! These are kept for handy use and popped frequently without recourse to further medical advice. Over time, as the GC dose becomes less effective, they often simply increase the dose on their own. It’s important to note that in India, most drugs, especially GCs, can be obtained over the counter without prescription. The appearance of such patients when they finally decide to return to the rheumatologist after a gap of five years or so for further treatment is familiar to rheuma­tologists, especially of my generation: what we used to call a steroid wreck—an obese, wheelchair-bound, semi-blind person with advanced Cushingoid features, extensive steroid purpura, some healed and some not-so-well-healed fractures, diabetes and hypertension, along with advanced joint damage and deformities.
Glucocorticoid Use for Rheumatoid Arthritis Still Sparks Debate
After dealing with such patients for 47 years, I have two important take-home lessons. First, pharmaceutical companies should change the taste: Prednisolone tablets are easy on the palate. If a GC pill were extremely bitter, it might discourage casual popping, as people do with gum or candy, whenever there is pain. Methylprednisolone (MP) is such a tablet. In addition to being more expensive, it tastes horrible, so bitter that patients plead with me not to prescribe it. So I started substituting MP for prednisolone.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Drug Updates, Rheumatoid Arthritis Tagged With: Asian–Indian, Drugs, glucocorticoid, patient care, Rheumatoid arthritis, Safety, TreatmentIssue: June 2015

You Might Also Like:
  • Glucocorticoid Use in Rheumatoid Arthritis Management Focus of Ongoing Debate
  • 2013 ACR/ARHP Annual Meeting: The Rheumatoid Arthritis Treatment Debate
  • Remission of Rheumatoid Arthritis Tied to Lower Risk of Metabolic Syndrome
  • Letters: Biomarkers for Rheumatoid Arthritis

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)